Medscape5d
Despite Early Promise GLP-1 Disappoints in Parkinson’s Disease
Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...
From fingers to toes, wearable and vibrating technology could help Parkinson's patients
Fingernail-sized vibrating gadgets, similar to the tiny devices that make your cellphone buzz, could help people with ...
New research uncovers brain changes in Parkinson's disease
Researchers at Karolinska Institutet have discovered new insights into brain changes in Parkinson's disease using advanced ...
Severe hand tremors? Lesioning surgery can fix it in one hour. Here's how it works for Parkinson’s, dystonia patients
Life-changing treatment for hand tremors in Parkinson’s and dystonia patients: Doctor reveals all you need to know about how ...
Global study identifies markers for the five clinical stages of Parkinson's disease
From a study that analyzed brain images of more than 2,500 people with Parkinson's disease in 20 different countries, ...
Armed robbery in Revesby13h
Research Reveals Brain Changes in Parkinson's Disease
Researchers at Karolinska Institutet have discovered new insights into brain changes in Parkinson's disease using advanced ...
The surprising way scientists say smokers can ease nicotine withdrawal
Now, scientists in Korea have discovered that the Parkinson’s disease drug procyclidine can alleviate physical symptoms of ...
SAAD Healthcare Parkinson’s disease patients fight back at Rock Steady boxing classes
In D’Iberville, those battling Parkinson’s Disease are slipping on the gloves and fighting back thanks to SAAD Healthcare’s Rock Steady Boxing classes.
AstraZeneca’s diabetes drug fails to slow Parkinson’s progression in UCL trial
Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...
Pharmaceutical Technology6d
Supernus wins FDA approval for Parkinson’s pump on fourth try
The US Food and Drug Administration (FDA) rejected three prior regulatory applications before granting approval.
HealthDay on MSN5d
Study Finds Exenatide Not Beneficial for Parkinson Disease
The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease seve ...
Pharm Exec5d
FDA Approves Supernus Pharmaceuticals’ Onapgo for Managing Motor Fluctuations in Parkinson Disease
Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing ...